High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjunction therewith
AssigneeNew York Blood Center, Inc.
InventorsPablo Rubinstein, Philip Henry Coelho, Cladd E. Stevens
Life of this patent
Estimating the term…
Abstract
A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.
Claims24
A system for concentrating blood cells, comprising in combination:
- a first blood bag adapted to receive blood from a source,
- means within said blood bag to prevent coagulation,
- reagent means removably coupled to said blood bag,
- means for separating white blood cells containing plasma supernatant from said first blood bag and into a satellite white cell bag,
- means for separating white cells from the plasma in said white cell bag, and
- a satellite plasma bag removably coupled to said white cell bag for receiving the expressed supernatant plasma from said white cell bag.
A method for concentrating placental stem cells, comprising the steps of:
- placing blood into a first blood bag,
- preventing coagulation within said blood bag,
- coupling reagent means into said blood bag,
- separating supernatant from said first blood bag and placing the supernatant into a white cell bag,
- separating white cells from plasma in said white cell bag,
- and removably coupling a plasma bag to said white cell bag and expressing the plasma from the white cell bag into said plasma bag.
A therapeutic product comprising white blood cells in a solution having a constituent presence of at least one white cell part per one hundred red cells and a stem and progenitor cell viability greater than 80%.
The product of 18 wherein there is a reduction of 90% of the red cells from an original blood donation.
A therapeutic product comprising white blood cells in a solution having a constituent presence of at least one white blood cell per one hundred red blood cells formed form the process of:
- placing blood into a first blood bag,
- preventing coagulation within said blood bag,
- coupling reagent means into said blood bag,
- separating supernatant from said first blood bag and placing the supernatant into a white cell bag,
- separating white cells from plasma in said white cell bag,
- removably coupling a plasma bag to said white cell bag and expressing the plasma from the white cell bag into said plasma bag,
- coupling cryoprotectant means to said white cell bag,
- transferring contents from said white cell bag to a stem cell freezing bag,
- freezing the contents of the stem cell freezing bag,
- sequestering the contents in said stem cell freezing bag into a plurality of partitioned areas prior to freezing the contents,
- labeling the partitioned areas of the stem cell freezing bag to identify the source of the cells contained therewithin,
- removing one of the partitions from the stem cell freezing bag to confirm the contents,
- thawing the contents of the stem cell freezing bag upon ascertaining the matching of that bag,
- washing cryoprotectant from the contents of one partitioned area of the stem cell freezing bag, and
- diluting the washed contents of the stem cell freezing bag and injecting the contents into a patient.
Dependencies are inferred from the claim text.